

리스페리돈을 복용한 여성 환자에서 유발된 무월경의 치료*

이분희** · 김용구**† · 한창수** · 고영훈**

The Resolution of Amenorrhea in Female Patients Taking Risperidone*

Bun-Hee Lee, M.D.,** Yong-Ku Kim, M.D.,**†
Chang-Su Han, M.D.,** Young-Hoon Ko, M.D.**

ABSTRACT

Objective : To find out the optimal assessment that can relieve amenorrhea associated with risperidone.

Methods : Sixteen female outpatients who have taken risperidone for more than 3 months reported voluntarily amenorrhea during Nov 2001 to May 2002. Since the reports of the amenorrhea, the resolution of amenorrhea has been prospectively followed during the next six months. The dosage of risperidone was reduced or discontinued in nine of sixteen patients, while risperidone was switched to olanzapine or quetiapine in other 7 patients according to the clinician's decision.

Results : Fourteen of 16 patients showed higher levels of prolactin than normal level. Five patients of the risperidone - reduction group recovered from the amenorrhea while all subjects of the drug - switch group recovered. The resolved patients of the former group recovered from amenorrhea in the dosage below 3mg per day of risperidone. Two patients of the risperidone - reduction group were dropped out during the reduction.

Conclusion : These findings suggest that risperidone - induced amenorrhea may be alleviated by reducing dosage to less 3mg per day(including discontinuation) or by switching to other antipsychotic drugs. Whether we would choose which method depends on patient's clinical status, diagnosis, and dose of medication and so on.

KEY WORDS : Risperidone · Amenorrhea · Schizophrenia · Mania · Depression.

서 론

D2 - 가 (pro-
가 , lactin - elevating antipsychotic drug) -

2003 6 28

WFSBP Asian congress

Department of Psychiatry College of Medicine, Korea University Ansan Hospital, Ansan, Korea

†교신저자 : , 425 - 020 1 516
) (031) 412 - 5140,) (031) 412 - 5144 E - mail) yongku@korea.ac.kr

가
drug)

(prolactin - sparing antipsychotic

연구 대상 및 방법

1. 연구 대상

2001 11 2002 5

17 3

2)3)

4-6)

가

1

가

16

가

가 16

16

1

Table 1. Information regarding patients with risperidone induced amenorrhea

Patient	Age	Diagnosis	Drugs & Doses	Length of taking risperidone	Prolactin (ng/mL)	Presenting symptoms
1	31	BID*	Risperidone 0.5mg/day Valproate sodium 500mg/day	50 months	11.5	Amenorrhea
2	34	BID	Risperidone 2mg/day Valproate sodium 750mg/day	12 months	25.0	Amenorrhea
3	34	MDD [†]	Risperidone 2mg/day Venlafaxine 150mg/day	12 months	97.0	Amenorrhea
4	43	SPR [‡]	Risperidone 2mg/day	60 months	104.6	Amenorrhea
5	39	ScA [§]	Risperidone 2mg/day Fluoxetine 20mg/day	60 months	72.0	Amenorrhea
6	37	SPR	Risperidone 4mg/day	11 months	95.9	Amenorrhea
7	28	SPR	Risperidone 8mg/day	7 months	68.0	Amenorrhea
8	33	SPR	Risperidone 6mg/day	6 months	243.0	Amenorrhea
9	42	SPR	Risperidone 7mg/day	7 months	119.0	Amenorrhea Galactorrhea
10	28	SPR	Risperidone 6mg/day	16 months	70.0	Amenorrhea
11	34	SPR	Risperidone 6mg/day	4 months	130.0	Amenorrhea
12	36	BID	Risperidone 4mg/day Lithium 600mg/day	4 months	94.6	Amenorrhea Galactorrhea
13	43	SPR	Risperidone 4mg/day	4 months	96.2	Amenorrhea Galactorrhea
14	37	SPR	Risperidone 5mg/day	4 months	190.0	Amenorrhea Galactorrhea
15	33	SPR	Risperidone 8mg/day	3 months	113.0	Amenorrhea
16	29	SPR	Risperidone 7mg/day	5 months	154.0	Amenorrhea

* : Bipolar I disorder, † : Major depressive disorder, ‡ : Schizophrenia, § : Schizoaffective disorder

35.1 ± 5.0 (28~42) , 2), 1 lithium(12) ,
 가 . 6.2 ± 1 venlafaxine(3), 1 fluoxetine
 5.6 (0.5~20) , 2 (5) .
 . DSM - 0.5mg 1
 , 3 11 , 1 0.5~2mg
 , 1 2 15 lorazepam
 2~8mg 0.5~2mg .
 , 2mg 2 (1 4) 16 14
 4mg 가 (68.0~243ng/mL , 117.6ng/mL).
 0.5~ 2 (1 2) 가
 8mg , 2mg (11.5 25.0ng/mL).
 5 11 4mg 14 4 (9, 12, 13, 14)
 (94~190ng/mL ,
 가 . 124.7ng/mL).
 12

2. 무월경에 대한 처치와 추적 관찰

12 (12 ~18) 16 , 9
 5 (1~3, 6~11)
 2 valproate sodium(1 , 7 (4~6, 12~16)

Table 2. Effect of treatment on amenorrhea in female patients

Patient	Pre-PRL*	Post-PRL †	Treatment	Effect of treatment
1	11.5	9.0	Stopped Risperidone	Periods returned after 3 weeks
2	25.0	12.1	Reduced dosage of Risperidone to 1mg/day	Periods returned after 3 weeks
3	97.0	20.8	Stopped Risperidone	Periods returned after 5 weeks
4	104.6	12.8	Switched to Olanzapine 2.5mg/day	Periods returned after 3 weeks
5	72.0		Switched to Olanzapine 5mg/day	Periods returned after 12 weeks
6	95.9	37.0	Reduced dosage of Risperidone to 1mg/day and then Switched to Olanzapine 20mg/day	Periods returned on Olanzapine Pregnancy
7	68.0		Reduced dosage of Risperidone to 3mg/day	Periods did not return Dropped out
8	243.0		Reduced dosage of Risperidone to 3mg/day	Periods did not return Dropped out
9	119.0	38.3	Reduced dosage of Risperidone to 5mg/day and Added Bromocriptine 2.5mg/day	Periods returned on bromocriptine 2.5mg/day for 2 weeks
10	70.0	31.0	Reduced dosage of Risperidone to 3mg/day	Periods returned after 12 weeks
11	130.0	45.4	Reduced dosage of Risperidone to 3mg/day	Periods returned after 8 weeks
12	94.6		Switched to Olanzapine 5mg/day	Periods returned after 9 weeks
13	96.2	9.1	Switched to Quetiapine 400mg/day	Periods returned after 8 weeks
14	190.0		Switched to Olanzapine 5mg/day	Periods returned after 7 weeks
15	113.0		Switched to Olanzapine 10mg/day	Periods returned after 4 weeks
16	154.0	23.0	Switched to Olanzapine 15mg/day	Periods returned after 6 weeks

* : Serum prolactin level before treatment for amenorrhea(ng/mL)

† : Serum prolactin level at the resolution of amenorrhea(ng/mL)

가 가

(2).

6

가
12 4mg
가

결 과

가

1. 리스페리돈 감량 또는 중단

(55.6%) (2).

1 2

2mg

가

고 찰

, 3

3

가

2)7)

5

가

가

6

(6~11)

Kim 2)

3mg

2

4mg

2mg

가 5

7 8

2mg

1

가

가

9

3mg

, 가 가

D2

5mg

bromocriptine

2.5mg 2 가

3~4mg

6

1mg

D2

80~90%가

7

가

8)

4

가

9) 가

2. 항정신병약물의 전환

4 5 12 16 7

tochrome P450 isoenzyme CYP 2D6

cy-

9 - hydroxyrisperidone

(2).

3~12

10)

slow metabolizer

(100%).

4 5

2mg

가

가
 , 16)17) , , 1)
 , 2) , 3)
 , 4)
 bromocriptine 가 ,
 11)12) 5)
 가
 (gonadotropin)
 가
 Turrone 13)
 tonic
 pattern 2
 가 가 16 8
 가 가
 12 , 가
 가 9
 가 가 bromocriptine
 가 4 가 가
 가 12 18 가
 가
 8~12 ,
 가
 14)15)
 가
 3mg 가 ,
 가
 4mg 가 18) , , 가
 (100mg/day)
 가 19)
 가
 가

가

가

중심 단어 :

참고문헌

1. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. *J Clin Psychiatry* 2002;63 (Suppl 4):56-62.
2. Kim YK, Kim L, Lee MS. Risperidone and associated amenorrhea: a report of 5 cases. *J Clin Psychiatry* 1999; 60:315-317.
3. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. *Clin Ther* 2000;22:1085-1096.
4. Canuso CM, Hanau M, Jhamb KK, Green AI. Olanzapine use in women with antipsychotic-induced hyperprolactinemia. *Am J Psychiatry* 1998;155:1458.
5. Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. *J Clin Psychiatry* 2002;63:408-413.
6. Haddad PM, Helleweil JS, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. *J Psychopharmacol* 2001;15:293-295.
7. Dickson RA, Dalby JT, Williams R, Edwards AL. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. *Am J Psychiatry* 1995;152: 1102-1103.
8. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. *Am J Psychiatry* 1999; 156:869-875.
9. Bowden CR, Voina SJ, Woestenborghs R, De Coster R, Heykants J. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. *J Pharmacol Exp Ther* 1992;262:699-706.
10. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. *Clin Pharmacol Ther* 1992;51:388-397.
11. Carter DA, McGarrick GM, Norton KR, Paykel ES, Pryor-Jones RA, Whitehead SA. The effect of chronic neuroleptic treatment on gonadotrophin release. *Psychoneuroendocrinology* 1982;7:201-207.
12. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. *Psychiatry Res* 2002;111:11-20.
13. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. *Am J Psychiatry* 2002;159:133-135.
14. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. *Psychoneuroendocrinology* 2003;28:55-68.
15. Kleinberg DL, David JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. *J Clin Psychopharmacology* 1999;19:57-61.
16. Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. *J Clin Psychiatry* 2000;61 (Suppl 3):10-15.
17. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. *Psychopharmacol Bull* 2002;36:143-164.
18. Ghaemi SN, Sachs GS, Baldassano CF, Truman CJ. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. *Can J Psychiatry* 1997;42: 196-199.
19. Sommers DK, Snyman JR, van Wyk M, Blom MW, Huang ML, Levron JC. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. *Int Clin Psychopharmacol* 1997;12:141-145.